Drug Interaction Study of Digoxin and BI 10773

Phase 1 Completed 20 enrolled Boehringer Ingelheim

RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the study is to investigate the relative bioavailability of digoxin after concomitant multiple oral administration of BI 10773 and a single dose of digoxin in comparison to digoxin given alone to healthy male and female subjects.

Timeline

Start: 2011-02
Primary completion: 2011-04
Completion: —

Publications

Macha S, Sennewald R, Rose P, Schoene K, Pinnetti S, Woerle HJ, Broedl UC. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013 Mar;35(3):226-35. doi: 10.1016/j.clinthera.2013.02.015.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Digoxin	Other / unclassified	0.5 mg	Oral
Subject	Empagliflozin	Small molecule	25 mg	Oral

Indications

No indication recorded.